ReviewFuture medicinal chemistry2012
Pharmacokinetic strategies for treatment of drug overdose and addiction.
Review in Future medicinal chemistry, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 71 citations in OpenAlex.
- AT1R in Central Nervous System Disorders: Unveiling Novel Mechanisms and Therapeutic Avenues for Addiction.Addiction biology · 2026Review
- Molecular recognition properties of water-soluble Prism[5]arene towards drugs of abuse.Supramolecular chemistry · 2026Article
- Fentanyl-Antibody Interaction as a Novel Strategy against Opiates and Opioids Abuse.Journal of medicinal chemistry · 2025Review
- Insoluble methylene-bridged glycoluril dimers as sequestrants for dyes.Beilstein journal of organic chemistry · 2025Article
- Amide naphthotube as a novel supramolecular sequestration agent for tetracaine and decamethonium.Theranostics · 2024Article
- An Engineered Human-Antibody Fragment with Fentanyl Pan-Specificity That Reverses Carfentanil-Induced Respiratory Depression.ACS chemical neuroscience · 2023Article
- An Engineered Human-Antibody Fragment with Fentanyl Pan-Specificity that Reverses Carfentanil-Induced Respiratory Depression.bioRxiv : the preprint server for biology · 2023Article
- Catalytic Antibody Blunts Carfentanil-Induced Respiratory Depression.ACS pharmacology & translational science · 2023Article
- Article
- Development of a vaccine against the synthetic opioid U-47700.Frontiers in pharmacology · 2023Article
- Kahweol, a coffee diterpene, increases lifespan via insulin/insulin-like growth factor-1 and AMP-activated protein kinase signaling pathways inCurrent research in food science · 2023Article
- Anthracene-Walled Acyclic CB[n] Receptors: in vitro and in vivo Binding Properties toward Drugs of Abuse.ChemMedChem · 2022Article
- In Vitro and In Vivo Sequestration of Methamphetamine by a Sulfated Acyclic CB[n]-Type Receptor.Chemistry (Weinheim an der Bergstrasse, Germany) · 2021Article
- In Vitro and In Vivo Sequestration of Phencyclidine by MeChemistry (Weinheim an der Bergstrasse, Germany) · 2021Article
- Attenuating nicotine's effects with high affinity human anti-nicotine monoclonal antibodies.PloS one · 2021Article
- The Individualized Management Approach for Acute Poisoning.Advances in pharmacological and pharmaceutical sciences · 2021Review
- Supramolecular hosts as in vivo sequestration agents for pharmaceuticals and toxins.Chemical Society reviews · 2020Review
- Sulfonate-isosteric replacement examined within heroin-hapten vaccine design.Bioorganic & medicinal chemistry letters · 2020Article
- A plant-derived cocaine hydrolase prevents cocaine overdose lethality and attenuates cocaine-induced drug seeking behavior.Progress in neuro-psychopharmacology & biological psychiatry · 2020Article
- Enhancement of a Heroin Vaccine through Hapten Deuteration.Journal of the American Chemical Society · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
The pharmacokinetic treatment strategy targets the drug molecule itself, aiming to reduce drug concentration at the site of action, thereby minimizing any pharmacodynamic effect. This approach might be useful in the treatment of acute drug toxicity/overdose and in the long-term treatment of addiction. Phase IIa controlled clinical trials with anticocaine and antinicotine vaccines have shown good tolerability and some efficacy, but Phase IIb and III trials have been disappointing because of the failure to generate adequate antibody titers in most participants. Monoclonal antibodies against cocaine, methamphetamine and phencyclidine have shown promise in animal studies, as has enhancing cocaine metabolism with genetic variants of human butyrylcholinesterase, with a bacterial esterase, and with catalytic monoclonal antibodies. Pharmacokinetic treatments offer potential advantages in terms of patient adherence, absence of medication interactions and benefit for patients who cannot take standard medications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.